The role of FDG-PET scan in staging patients with nonsmall cell carcinoma

Annals of Thoracic Surgery

Volumn 76, Issue 3, 2003, Pages 861-866

  Cerfolio, Robert J ^a   Ojha, Buddhiwardhan ^b   Bryant, Ayesha S ^b   Bass, Cynthia S ^b   Bartalucci, Alfred A ^b   Mountz, James M ^b  

^a Kentucky   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE;

ABDOMEN; ACCURACY; ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LABORATORY DIAGNOSIS; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LYMPH NODE; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MEDIASTINOSCOPY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; THORAX;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MEDIASTINOSCOPY; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0042832570     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(03)00888-9     Document Type: Article

References (24)

1. Depierre A, Milleron B, Moro-Sibilot, D, et al. Preoperatie chemotherapy followed by surgery compared with primary surgery in resectable stage 1 (except T1N0), II, and IIIa non-small cell lung cancer. J Clin Oncol 2002;20:247-53.
2. Mountain CF. Revisions in the international systems for staging lung cancer. Chest 1997;111:1710-7.
3. Gould MK, Maclean CC, Kuschner WG, et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules, and mass lesions. JAMA 2001;285:914-24.
4. McCain TW, Dunagan DP, Chin R, et al. The usefulness of positron emission tomography in evaluating patients for pulmonary malignancies. Chest 2000;118:1610-5.
5. Gupta NC, Graeber GM, Bishop HA, et al. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small, intermediate, and large lymph node lesions. Chest 2000;117:773-8.
6. Pieterman RM, van Putten JWG, Meuzelaar JJ, et al. Preoperative staging of non-small cell lung cancer with positron emission tomography. N Engl J Med 2000;343:254-61.
7. Dietlein M, Weber K, Detlef M, et al. Cost-effectiveness of FDG-PET for the management of potentially operable non-small lung cancer. Priority for a PET-based strategy after nodal negative CT results. Eur J Nucl Med 2000;27:1598-609.
8. Roberts PF, Follette DM, von Haag D, et al. Factors associated with false-positive staging of lung cancer by positron emission tomography. Ann Thor Surg 2000;70:1154-60.
9. Hagge RJ, Wong TZ, Coleman RE, et al. Positron emission tomography: brain tumors and lung cancer. Radiol Clin North Am 2001;39:871-81.
10. Savelli G, Maffioli L, Maccauro M, et al. Bone scintigraphy and the added value of SPECT in detecting skeletal lesions. Q J Nuclear Med 2001;45:27-37.
11. Strauss LG. Sensitivity and specificity of positron emission tomography for the diagnosis of lymph node metasases. Cancer Res 2000;157:12-9.
12. Boiselle PM. MR imaging of thoracic lymph nodes. A comparison of computed tomography and positron emission tomography. Magn Reson Imaging Clin N Am 2000;8:33-41.
13. Al-Sugair A, Coleman RE. Applications of PET in lung cancer. Semin Nucl Med 1998;28:303-19.
14. Boiselle PM, Patz EF JR, Vining DJ, et al. Imaging of mediastinal lymph nodes: CT, MR, and FDG-PET. Radiographics 1998;18:1061-9.
15. Poncelet AJ, Lonneux M, Coche E, et al. PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma. Eur J Cardiothorac Surg 2001;20:468-75.
16. Liewald F, Grobe S, Guhlman A, et al. How useful is PET for lymph node staging in non-small cell lung cancer? Thor Cardiovasc Surg 2000;48:93-6.
17. Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41:1369-79.
18. Vesselle H. The impact of fluorodeoxyglucose F-18 positron emission tomography on the surgical staging of non-small cell cancer. J Thorac Cardiovasc Surg 2002;124:511-9.
19. Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo P. Flourine-18-deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998;25:1244-7.
20. Erasmus JJ, Patz EF, McAdams HP, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-flourodexoxyglycose positron emission tomography. Am J Roentgenol 1997;168:1357-60.
21. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s meta-analytic comparison of PET and CT. Radiology 2002;213:530-5.
22. Graeter TP, Hellwig D, Hoffmann K, et al. Mediastinal lymph nodes staging in suspected lung cancer: comparison of positron emission tomography with F-18 flourodeoxyglucose and mediastinoscopy. Ann Thor Surg 2003;75:231-6.
23. Cerfolio RJ, Bryant AS, Ojha B. The accuracy of PET-CT compared to PET alone for the staging of patients with non-small cell lung cancer. In press.
24. Cerfolio RJ, Ojha B, Mukherjee S, et al. Positron emission tomography scanning with 2-fluoro-2-deoxy-D-glucose as a predictor of response of neo-adjuvant treatment for non-small cell carcinoma. J Thorac Cardiovasc Surg 2003;125:938-44.